Heart failure outcomes by left ventricular ejection fraction in a contemporary region-wide patient cohort.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: John Wiley & Sons Ltd on behalf of the European Society of Cardiology Country of Publication: England NLM ID: 101669191 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2055-5822 (Electronic) Linking ISSN: 20555822 NLM ISO Abbreviation: ESC Heart Fail Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Oxford] : John Wiley & Sons Ltd on behalf of the European Society of Cardiology, [2014]-
    • Subject Terms:
      Heart Failure*/physiopathology ; Heart Failure*/epidemiology ; Stroke Volume*/physiology ; Ventricular Function, Left*/physiology; Humans ; Female ; Male ; Aged ; Sweden/epidemiology ; Incidence ; Prognosis ; Follow-Up Studies ; Prevalence ; Echocardiography ; Aged, 80 and over
    • Abstract:
      Aims: This study aimed to characterize a contemporary population with subtypes of incident or prevalent heart failure (HF) based on reduced (HFrEF), mildly reduced, or preserved (HFpEF) left ventricular ejection fraction (LVEF) and to assess how outcomes, healthcare, treatments, and healthcare costs vary between each subtype of incident HF.
      Methods and Results: Using Swedish data from the CardioRenal and Metabolic disease Heart Failure (CaReMe HF) study, updated to cover a more recent time period, this population-based study characterized patients from Stockholm County, Sweden, with incident HF (patients with a first HF diagnosis between 1 January 2015 and 31 December 2019) or prevalent HF (patients with a first HF diagnosis before 1 January 2020). Patients with incident HF had LVEF measured by echocardiography within ±90 days of their first HF diagnosis, and patients with prevalent HF within 5 years prior to the index date. The 13 375 patients with prevalent HF (39.2% women, mean age 73.9 years) had multiple comorbidities (cardiovascular diseases, chronic kidney disease, diabetes, and cancer). These were already highly prevalent at the time of the first HF diagnosis in the 8042 patients with incident HF (40.5% women, mean age 72.3 years). Patients with incident HFpEF received less specialist HF care at outpatient secondary care facilities following their first HF diagnosis than those with incident HFrEF. Patients with HFrEF had higher risks of complications and exerted a higher burden, in terms of care for and costs of HF, on the healthcare system.
      Conclusions: This study of contemporary patients with incident HF demonstrates that those with HFpEF and HFrEF differ considerably in terms of clinical presentation, prognosis, and care, highlighting a potential to improve HF outcomes.
      (© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
    • References:
      Eur J Heart Fail. 2002 Jun;4(3):361-71. (PMID: 12034163)
      Eur Heart J Qual Care Clin Outcomes. 2022 Oct 26;8(7):750-760. (PMID: 34625809)
      Circulation. 2011 May 10;123(18):2006-13; discussion 2014. (PMID: 21555723)
      Heart. 2018 Apr;104(7):600-605. (PMID: 28982720)
      Eur Heart J. 2016 Jul 14;37(27):2129-2200. (PMID: 27206819)
      N Engl J Med. 2020 Oct 8;383(15):1413-1424. (PMID: 32865377)
      N Engl J Med. 2019 Nov 21;381(21):1995-2008. (PMID: 31535829)
      N Engl J Med. 2014 Sep 11;371(11):993-1004. (PMID: 25176015)
      N Engl J Med. 2022 Sep 22;387(12):1089-1098. (PMID: 36027570)
      Lancet. 2018 Feb 10;391(10120):572-580. (PMID: 29174292)
      Diab Vasc Dis Res. 2018 Nov;15(6):494-503. (PMID: 30176743)
      Card Fail Rev. 2017 Apr;3(1):7-11. (PMID: 28785469)
      ESC Heart Fail. 2024 Jun;11(3):1377-1388. (PMID: 38311878)
      Circulation. 2022 May 3;145(18):e895-e1032. (PMID: 35363499)
      Eur J Epidemiol. 2009;24(11):659-67. (PMID: 19504049)
      Eur J Heart Fail. 2017 Dec;19(12):1574-1585. (PMID: 28386917)
      N Engl J Med. 2021 Oct 14;385(16):1451-1461. (PMID: 34449189)
      Heart. 2023 Mar 10;109(7):548-556. (PMID: 36781285)
      Eur Heart J. 2021 Sep 21;42(36):3599-3726. (PMID: 34447992)
      Nat Rev Cardiol. 2022 Feb;19(2):100-116. (PMID: 34489589)
      Can J Cardiol. 2021 Apr;37(4):531-546. (PMID: 33827756)
      N Engl J Med. 2015 Jan 1;372(1):1-4. (PMID: 25551523)
    • Grant Information:
      AstraZeneca Mölndal
    • Contributed Indexing:
      Keywords: HFmrEF; HFpEF; HFrEF; Heart failure; Left ventricular ejection fraction
    • Publication Date:
      Date Created: 20240205 Date Completed: 20240516 Latest Revision: 20240614
    • Publication Date:
      20240614
    • Accession Number:
      PMC11098668
    • Accession Number:
      10.1002/ehf2.14685
    • Accession Number:
      38311878